Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH).

Leo Gu, Ph.D., Co-CEO and President of Selten Pharma, said, "We are pleased to receive Orphan Drug Designation for SPI-026, which highlights the significant need for new medications for patients suffering from PAH. We greatly appreciate the FDA's support of our efforts to evaluate our SPI-026 program for the treatment of PAH. The results of the proof-of-concept, safety, and tolerability study in this indication have been very encouraging."

"We are excited to begin the Phase 2b clinical trial of SPI-026, which we believe has the potential to be the first disease-modifying treatment for patients with this life threatening disease. SPI-026 has been shown to activate the BMPR2 pathway and possibly could even reverse the effects of the disease," commented Narinder S. Banait, Ph.D., J.D., Co-CEO and General Counsel of Selten Pharma.

SOURCE Selten Pharma, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Researchers discover blood gene signatures that can predict COVID-19 severity